WUNDERKIND
21.5.2024 15:01:26 CEST | Business Wire | Press release
Wunderkind, the leading AI-driven performance marketing solution, today announced the launch of its AI-powered Autonomous Marketing Platform and its first application, Studio, which brings self-service tools to the creative workflow for marketers and services teams.
Wunderkind’s Autonomous Marketing Platform leverages the power of artificial intelligence (AI) to streamline the entire marketing build, report and optimisation process. Through the analysis of trillions of behavioural data points, the platform uncovers valuable insights, facilitating the creation and execution of strategies that drive undeniable performance. The Wunderkind platform delivers on marketing use cases, such as making actionable data available through identity, leveraging AI to deliver omnichannel experiences, measuring insights and integrating with the broader martech ecosystem.
The Autonomous Marketing Platform is underpinned by the Wunderkind Identity Network, a proprietary Identity graph which recognises over 9 billion consumer devices, 1 billion opted-in consumer profiles and observes 2 trillion events per year. This allows Wunderkind to identify up to 50% more consumer profiles than leading email service providers (ESPs), enabling its AI-powered marketing engine to deliver significantly more personalised, 1:1 emails and text messages to drive ROI.
Studio, the First Application in the Platform Roadmap
As the critical marketing infrastructure for more than 700 brands and retailers, Wunderkind’s Studio streamlines the design process to create best-in-class brand experiences for the entire creative process. Studio provides the ability to make real-time creative edits to experiences, which is improving the time to build and launch campaigns by over 50% for Wunderkind clients. The Generative AI (Gen AI) capabilities in Studio empower marketers to quickly optimise their messaging, ensuring optimal conversions based on Wunderkind’s observation across trillions of consumer interactions.
Studio represents a watershed moment for Wunderkind, marking a significant evolution in its AI-driven product vision, which centres on providing adaptive learning and decisioning to proactively elevate marketing performance. Wunderkind’s roadmap includes additional AI-powered applications to further optimise the creation of bespoke customer experiences, robust audience development and deep analytics on engagement and revenue attribution.
This investment in the platform and its connected applications complements Wunderkind’s award-winning managed service offering, which delivers more than $5 billion in guaranteed revenue every year for brands such as Uniqlo, Sonos, Clarks and Kurt Geiger, and typically generates more than 10% of total digital revenue for clients.
“Our Autonomous Marketing Platform brings the full potential of our proprietary data and best practices to scale through AI,” Bill Ingram, CEO at Wunderkind, commented. “Studio significantly reduces the time spent on building marketing creatives and elevating outstanding performance. Wunderkind’s continued investments in AI allows us to deliver dynamic consumer experiences, which drive revenue while guiding brands through massive industry changes.”
Molly Delp, VP of eCommerce and Digital Marketing at skincare brand True Botanicals, commented: “We love Wunderkind because it's a managed service that lets us focus on our day-to-day while their professional services team delivers the engagement and eCommerce revenue lift we need. The launch of Studio brings speed and agility to our revenue strategy”.
Wunderkind will host a virtual public roadmap event on 26 June 2024, which will provide further details on its Autonomous Marketing Platform and other forthcoming applications planned to help marketers drive further enhanced performance and ROI. To register, sign up here.
Notes to editors
About Wunderkind
Wunderkind is the leading AI-driven performance marketing solution that collects consent-based, first-party data and identifies anonymous traffic for brands in order to scale hyper-personalised one-to-one messages. Brands lean on the Wunderkind Identity Network, a proprietary database recognising 9 billion devices and 1 billion opted-in consumers, observing 2 trillion digital transactions per year, to trigger the most impactful offers to their target audience at the right moment and in the right channel. This proprietary data is accessed by Wunderkind's autonomous AI engine, which integrates seamlessly into a brand's existing ESP, to boost performance across email, text and advertising channels.
Wunderkind is the only performance solution that guarantees a lift in revenue for its clients and delivers over $5 billion in directly attributable revenue annually for brands across a number of industries, often ranking as a top 3 revenue channel in clients' own analytics platforms. Brands such as Harley-Davidson, Perry Ellis and Shoe Carnival partner with Wunderkind to drive top-line revenue through its guaranteed results. To learn more, visit wunderkind.co.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240521214381/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
Sutherland Launches FinAI Hub to Industrialize Agentic AI for Banking and Financial Services6.3.2026 14:00:00 CET | Press release
A domain-trained AI agent workforce enables production-scale AI across regulated financial institution operations Today, Sutherland announced the launch of Sutherland FinAI Hub, an enterprise Agentic AI platform built exclusively for Banking and Financial Services. As financial institutions accelerate AI adoption, many initiatives remain confined to pilots, unable to scale across legacy systems and core operations. Sutherland FinAI Hub is designed to help close that gap. FinAI Hub is an innovation ecosystem where Sutherland works with clients to design, prototype, and scale Agentic AI workflows across core operations. At launch, the platform brings together a large and expanding workforce of domain-trained AI agents purpose-built for financial institutions, supporting functions across retail banking, payments, cards, consumer and commercial lending, servicing, back office, risk and compliance functions. These modular agents can operate independently or be orchestrated across end-to-end
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
